In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...
In April, CTS becomes the first blood donor testing organization in the US to implement Zika testing...